25,729 articles
MSC-PBC-I/II trial
MSC-PBC-I/II (NCT07795151) is a Beijing 302 Hospital phase I/II trial of human umbilical cord mesenchymal stromal cells for UDCA-refractory primary biliary cholangitis: 68 participants, 3+3 dose escalation then blinded placebo-controlled phase II with composite ALP/bilirubin response at week 12.
MSTO-211H
MSTO-211H (ATCC CRL-2081, DSMZ ACC 390, CVCL_1430) is a human biphasic pleural mesothelioma cell line established in 1985 from a 62-year-old man's pleural effusion, with fibroblast-like morphology, LATS1-PSEN1 fusion, and wide use in mesothelioma drug research.
MTA trial (NCT00000388)
MTA trial (NCT00000388), the Multimodal Treatment Study of Children with ADHD: NIMH 14-month randomized trial of 579 children comparing medication, behavior therapy, combination, and community care, with 16-year follow-up showing converging outcomes and stimulant-related growth suppression.
MTS-128
MTS-128 is a preclinical trispecific T-cell engager targeting CD19, BCMA, and CD3 with an HSA-binding half-life extension domain, developed by METiS TechBio's NanoForge AI platform for autoimmune disease and licensed globally to Boulevard Bio for $20 million upfront plus up to $1.6 billion in milestones.
MTSS trial (NCT05637476)
MTSS trial NCT05637476, a Cairo University single-blind randomized trial, tested functional hip abductor strength training plus physical therapy in 40 recreational runners with medial tibial stress syndrome, finding reduced knee valgus and pelvic drop versus physical therapy alone over 8 weeks.
MTX-13 (DAY301)
MTX-13, also called DAY301 or CB-002, is a PTK7-targeting antibody-drug conjugate (Ab13 plus T1000 linker carrying eight exatecan molecules) developed by Multitude Therapeutics and licensed to Day One Biopharmaceuticals in 2024; it is in Phase 1 testing for solid tumors.
Mucinous adenocarcinoma of ovary
Mucinous adenocarcinoma of ovary (ovarian mucinous adenocarcinoma, MOC), a rare 3–5% subtype of epithelial ovarian cancer; unilateral mucin-producing tumor, good early-stage prognosis, poor advanced-stage survival, expansile versus infiltrative WHO subtypes.
Mucinous cystadenocarcinoma of the pancreas
Mucinous cystadenocarcinoma of the pancreas (MCAC), also called pancreatic mucinous cystic neoplasm with associated invasive carcinoma, is the malignant grade of mucinous cystic neoplasm, arising almost exclusively in middle-aged women in the pancreatic body or tail, with about 60% five-year survival after resection.
Muckle-Wells syndrome
Muckle-Wells syndrome (MWS), an intermediate cryopyrinopathy within CAPS, is an autosomal dominant NLRP3-related autoinflammatory disease causing urticarial rash, recurrent fever, sensorineural hearing loss, and AA amyloidosis, treatable with IL-1 inhibitors.
Mucocele of appendix
Mucocele of appendix (appendiceal mucocele): mucin-filled cystic dilatation of the appendix, a descriptive term covering retention cysts through LAMN, HAMN, and mucinous adenocarcinoma; rupture risks pseudomyxoma peritonei; treated by appendectomy guided by pathology.
Mucociliary Clearance
Mucociliary clearance, also called mucociliary transport, is the lung's primary innate defense: cilia beating in metachronal waves propel a mucus layer trapping inhaled particles and pathogens out of the airways.
Mucocutaneous leishmaniasis
Mucocutaneous leishmaniasis (espundia, mucosal leishmaniasis), a Leishmania sandfly-borne disease destroying nose, mouth, and throat mucosa; mainly L. braziliensis in Bolivia, Brazil, Ethiopia, Peru; treated with pentavalent antimonials.
Mucocutaneous venous malformations
Mucocutaneous venous malformations, formally VMCM, are a rare hereditary vascular malformation causing small venous lesions of the skin and mucosa, inherited in an autosomal dominant pattern.
Mucolipidosis type II
Mucolipidosis type II, or I-cell disease (MLII alpha/beta), a severe autosomal recessive lysosomal storage disorder from GNPTAB mutations causing mannose-6-phosphate tagging failure, presenting at birth with dysostosis multiplex, cardiac and respiratory disease, and death in early childhood.
Mucolipidosis type III
Mucolipidosis type III (pseudo-Hurler polydystrophy), MLIII alpha/beta (GNPTAB) or gamma (GNPTG), is a rare autosomal recessive lysosomal storage disorder from partial GlcNAc-1-phosphotransferase deficiency, causing progressive joint stiffness, short stature, and dysostosis multiplex with median survival of 62 years.
Mucolipidosis type IV
Mucolipidosis type IV (MLIV, OMIM 252650) is an ultra-rare autosomal recessive lysosomal storage disorder caused by MCOLN1 mutations, marked by psychomotor delay, progressive vision loss, achlorhydria, and a 2026 FDA-authorized gene therapy trial.
Mucopenetrating nanoparticles
Mucopenetrating nanoparticles (MPPs), also called mucus-penetrating particles, are drug carriers whose dense PEG coating makes them muco-inert, allowing them to diffuse through mucus instead of being trapped by it.
Mucopolysaccharidosis
Mucopolysaccharidosis (MPS), also called mucopolysaccharidoses, is a group of rare inherited lysosomal storage diseases in which enzyme deficiency causes glycosaminoglycan buildup; types include Hurler, Hunter, Sanfilippo, and Morquio syndromes, treated with ERT, HSCT, and gene therapy.
Mucopolysaccharidosis type 1
Mucopolysaccharidosis type 1 (MPS I, Hurler syndrome, alpha-L-iduronidase deficiency) is a rare autosomal recessive lysosomal storage disorder causing dermatan and heparan sulfate accumulation, treated with HSCT and laronidase enzyme replacement therapy.
Mucopolysaccharidosis type 10
Mucopolysaccharidosis type 10 (MPS10, MPS type X, ARSK deficiency) is an autosomal recessive lysosomal storage disorder from biallelic ARSK variants on 5q15, causing childhood short-trunk short stature with skeletal, cardiac, and ophthalmologic findings but normal cognition.
Mucopolysaccharidosis type 6
Mucopolysaccharidosis type 6 (MPS VI, Maroteaux-Lamy syndrome) is a rare autosomal recessive lysosomal storage disease caused by arylsulfatase B (ARSB) deficiency, treated with galsulfase enzyme replacement therapy since 2005.
Mucopolysaccharidosis type 7
Mucopolysaccharidosis type 7 (MPS VII, Sly syndrome, beta-glucuronidase deficiency) is an ultra-rare autosomal recessive lysosomal storage disease caused by GUSB mutations, treated with vestronidase alfa enzyme replacement therapy.
Mucopurulent chronic bronchitis
Mucopurulent chronic bronchitis, also called chronic suppurative or purulent bronchitis, is chronic bronchitis with thick purulent sputum; ICD-11 CA20.11, ICD-10-CM J41.1, ICD-9 491.1, SNOMED CT 74417001.
Mucopurulent conjunctivitis
Mucopurulent conjunctivitis (ICD-11 9A60.3, ICD-10 H10.0), bacterial conjunctival infection with mucus-and-pus discharge and matted eyelids; usually self-limited, antibiotics modestly speed cure.
Mucormycosis
Mucormycosis, also known as black fungus, is a rare fungal infection caused by Mucorales molds, killing roughly half of those affected and requiring amphotericin B and surgery.
Mucosal ablation
Mucosal ablation is an endoscopic procedure that destroys abnormal mucosal tissue, most commonly precancerous Barrett's esophagus epithelium, using thermal methods like radiofrequency ablation and argon plasma coagulation, or nonthermal cryoablation.
Mucosal administration
Mucosal administration is a drug delivery route giving medication across mucosal membranes, including nasal, buccal, sublingual, rectal, vaginal, and ocular surfaces, allowing rapid uptake and avoiding first-pass metabolism.
Mucosal cyst of postmastoidectomy cavity
Mucosal cyst of postmastoidectomy cavity (ICD-11 AB91, ICD-10 H95.13, formerly ICD-9 383.31): a mucosa-lined cyst forming in the mastoid after mastoidectomy, presenting with discharge and hearing loss, treated by complete cyst wall removal.
Mucosal Immunity
Mucosal immunity: immune defense at the gastrointestinal, respiratory, and urogenital mucous membranes, mediated mainly by secretory IgA, distinct from systemic immunity and central to mucosal vaccine development.
Mucosal melanosis
Mucosal melanosis (ICD-11 ED61.1) is benign flat pigmentation of oral, genital, or conjunctival mucosa with normal melanocyte counts; it mimics mucosal melanoma, and conjunctival primary acquired melanosis can progress to melanoma.